​
​

Pacira BioSciences (PCRX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Pacira BioSciences Revenue Highlights

Latest Revenue (Y)

$674.98M

Latest Revenue (Q)

$168.57M

Main Segment (Y)

Product

Pacira BioSciences Revenue by Period

Pacira BioSciences Revenue by Year

DateRevenueChange
2023-12-31$674.98M1.22%
2022-12-31$666.82M23.14%
2021-12-31$541.53M28.68%
2020-12-31$420.83M-0.05%
2019-12-31$421.03M24.83%
2018-12-31$337.28M17.67%
2017-12-31$286.63M3.71%
2016-12-31$276.37M10.99%
2015-12-31$249.00M25.97%
2014-12-31$197.67M131.05%
2013-12-31$85.55M118.89%
2012-12-31$39.08M149.12%
2011-12-31$15.69M7.74%
2010-12-31$14.56M-2.96%
2009-12-31$15.01M7.76%
2008-12-31$13.93M-

Pacira BioSciences generated $674.98M in revenue during NA 2023, up 1.22% compared to the previous quarter, and up 200.13% compared to the same period a year ago.

Pacira BioSciences Revenue by Quarter

DateRevenueChange
2024-09-30$168.57M-5.31%
2024-06-30$178.02M6.53%
2024-03-31$167.12M-7.79%
2023-12-31$181.24M10.56%
2023-09-30$163.93M-3.27%
2023-06-30$169.47M5.69%
2023-03-31$160.34M-6.75%
2022-12-31$171.96M2.68%
2022-09-30$167.47M-1.15%
2022-06-30$169.41M7.23%
2022-03-31$157.99M-0.76%
2021-12-31$159.19M24.64%
2021-09-30$127.72M-5.80%
2021-06-30$135.59M13.92%
2021-03-31$119.03M-7.41%
2020-12-31$128.55M9.42%
2020-09-30$117.48M55.60%
2020-06-30$75.50M-28.56%
2020-03-31$105.68M-13.67%
2019-12-31$122.42M16.95%
2019-09-30$104.69M2.03%
2019-06-30$102.60M12.37%
2019-03-31$91.31M-4.00%
2018-12-31$95.11M13.98%
2018-09-30$83.45M-0.78%
2018-06-30$84.11M12.73%
2018-03-31$74.61M-5.65%
2017-12-31$79.08M17.44%
2017-09-30$67.33M-5.07%
2017-06-30$70.93M2.38%
2017-03-31$69.28M-4.96%
2016-12-31$72.90M6.65%
2016-09-30$68.36M-1.85%
2016-06-30$69.64M6.36%
2016-03-31$65.47M-5.55%
2015-12-31$69.32M11.43%
2015-09-30$62.21M5.18%
2015-06-30$59.15M1.43%
2015-03-31$58.32M-5.63%
2014-12-31$61.79M18.72%
2014-09-30$52.05M10.35%
2014-06-30$47.16M28.65%
2014-03-31$36.66M9.23%
2013-12-31$33.56M44.31%
2013-09-30$23.26M35.69%
2013-06-30$17.14M47.93%
2013-03-31$11.59M10.88%
2012-12-31$10.45M23.14%
2012-09-30$8.49M-31.25%
2012-06-30$12.34M58.18%
2012-03-31$7.80M84.36%
2011-12-31$4.23M7.00%
2011-09-30$3.96M8.80%
2011-06-30$3.64M-5.88%
2011-03-31$3.86M76.31%
2010-12-31$2.19M-51.65%
2010-09-30$4.53M48.35%
2010-06-30$3.06M-36.14%
2010-03-31$4.78M11.67%
2009-12-31$4.28M13.94%
2009-09-30$3.76M-

Pacira BioSciences generated $168.57M in revenue during Q3 2024, up -5.31% compared to the previous quarter, and up 99.47% compared to the same period a year ago.

Pacira BioSciences Revenue Breakdown

Pacira BioSciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Bupivacaine Liposome Injectable Suspension$3.34M$6.48M$3.61M--
EXPAREL$538.12M$536.90M$506.51M--
Product$672.25M$664.15M$426.61M--
ZILRETTA$111.10M$105.52M$12.68M--
Royalty---$3.03M-
EXPAREL/bupivacaine liposome injectable suspension----$411.03M
DepoCyte-----

Pacira BioSciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (50.74%), EXPAREL (40.62%), ZILRETTA (8.39%), and Bupivacaine Liposome Injectable Suspension (0.25%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
ZILRETTA$28.42M$30.71M$25.84M$28.70M$28.80M$29.26M$24.33M$27.97M$26.49M$27.42M$23.64M---------
Product$167.72M$176.39M$165.82M$179.76M$163.58M$169.47M$159.43M$171.59M$166.56M$168.58M$157.42M$126.79M$134.86M$118.74M$129.76M$116.89M$75.22M$104.75M$121.85M$104.35M
EXPAREL$132.00M$136.85M$132.43M-----------------
Bupivacaine Liposome Injectable Suspension$1.64M$3.15M$2.52M$1.10M$858.00K$695.00K$688.00K$1.01M$2.96M$956.00K$1.56M---------
EXPAREL/bupivacaine liposome injectable suspension----$128.67M$135.13M$130.41M$132.64M$137.01M$129.21M$115.47M---------
Royalty-----------$931.00K$602.00K$1.21M$595.00K$289.00K$939.00K$578.00K$335.00K-
Collaborative Licensing and Milestone Revenue------------$125.00K-------

Pacira BioSciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (50.86%), EXPAREL (40.03%), ZILRETTA (8.62%), and Bupivacaine Liposome Injectable Suspension (0.50%).

Pacira BioSciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories$279.16B-
ALKSAlkermes$1.66B$378.14M
PBHPrestige Consumer Healthcare$1.13B$283.55M
PAHCPhibro Animal Health$977.89M$273.16M
HCMHUTCHMED (China)$838.00M$152.56M
PCRXPacira BioSciences$674.98M$168.57M
COLLCollegium Pharmaceutical$566.77M$159.30M
ANIPANI Pharmaceuticals$486.82M$148.33M
ITCIIntra-Cellular Therapies$462.18M$175.38M
EGRXEagle Pharmaceuticals$316.61M$64.65M
DCPHDeciphera Pharmaceuticals$163.36M$45.00M
SSICSilver Spike Investment$11.72M$2.76B
IXHLIncannex Healthcare-$12.00K

PCRX Revenue FAQ

What is Pacira BioSciences’s yearly revenue?

Pacira BioSciences's yearly revenue for 2023 was $674.98M, representing an increase of 1.22% compared to 2022. The company's yearly revenue for 2022 was $666.82M, representing an increase of 23.14% compared to 2021. PCRX's yearly revenue for 2021 was $541.53M, representing an increase of 28.68% compared to 2020.

What is Pacira BioSciences’s quarterly revenue?

Pacira BioSciences's quarterly revenue for Q3 2024 was $168.57M, a -5.31% decrease from the previous quarter (Q2 2024), and a 2.83% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $178.02M, a 6.53% increase from the previous quarter (Q1 2024), and a 5.05% increase year-over-year (Q2 2023). PCRX's quarterly revenue for Q1 2024 was $167.12M, a -7.79% decrease from the previous quarter (Q4 2023), and a 4.23% increase year-over-year (Q1 2023).

What is Pacira BioSciences’s revenue growth rate?

Pacira BioSciences's revenue growth rate for the last 3 years (2021-2023) was 24.64%, and for the last 5 years (2019-2023) was 60.32%.

What are Pacira BioSciences’s revenue streams?

Pacira BioSciences's revenue streams in c 23 are Bupivacaine Liposome Injectable Suspension, EXPAREL, Product, and ZILRETTA. Bupivacaine Liposome Injectable Suspension generated $3.34M in revenue, accounting 0.25% of the company's total revenue, down -48.39% year-over-year. EXPAREL generated $538.12M in revenue, accounting 40.62% of the company's total revenue, up 0.23% year-over-year. Product generated $672.24M in revenue, accounting 50.74% of the company's total revenue, up 1.22% year-over-year. ZILRETTA generated $111.1M in revenue, accounting 8.39% of the company's total revenue, up 5.29% year-over-year.

What is Pacira BioSciences’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Pacira BioSciences was Product. This segment made a revenue of $672.24M, representing 50.74% of the company's total revenue.